vs
Side-by-side financial comparison of BYLINE BANCORP, INC. (BY) and Esperion Therapeutics, Inc. (ESPR). Click either name above to swap in a different company.
Esperion Therapeutics, Inc. is the larger business by last-quarter revenue ($168.4M vs $112.4M, roughly 1.5× BYLINE BANCORP, INC.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 9.0%). Over the past eight quarters, Esperion Therapeutics, Inc.'s revenue compounded faster (10.6% CAGR vs 6.4%).
Byline Bank is a bank headquartered in Chicago, Illinois, United States. It is the primary subsidiary of Byline Bancorp, Inc., a bank holding company, and the 4th largest SBA 7(a) lender.
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
BY vs ESPR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $112.4M | $168.4M |
| Net Profit | $37.6M | — |
| Gross Margin | — | — |
| Operating Margin | — | 50.6% |
| Net Margin | 33.4% | — |
| Revenue YoY | 9.0% | 143.7% |
| Net Profit YoY | 33.0% | — |
| EPS (diluted) | $0.83 | $0.32 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | $112.4M | — | ||
| Q4 25 | $117.0M | $168.4M | ||
| Q3 25 | $115.7M | $87.3M | ||
| Q2 25 | $110.5M | $82.4M | ||
| Q1 25 | $103.1M | $65.0M | ||
| Q4 24 | $104.7M | $69.1M | ||
| Q3 24 | $101.8M | $51.6M | ||
| Q2 24 | $99.4M | $73.8M |
| Q1 26 | $37.6M | — | ||
| Q4 25 | $34.5M | — | ||
| Q3 25 | $37.2M | $-31.3M | ||
| Q2 25 | $30.1M | $-12.7M | ||
| Q1 25 | $28.2M | $-40.5M | ||
| Q4 24 | $30.3M | — | ||
| Q3 24 | $30.3M | $-29.5M | ||
| Q2 24 | $29.7M | $-61.9M |
| Q1 26 | — | — | ||
| Q4 25 | 40.1% | 50.6% | ||
| Q3 25 | 43.1% | -11.4% | ||
| Q2 25 | 35.2% | 8.6% | ||
| Q1 25 | 36.4% | -34.0% | ||
| Q4 24 | 38.6% | -6.4% | ||
| Q3 24 | 39.3% | -31.0% | ||
| Q2 24 | 40.4% | 3.5% |
| Q1 26 | 33.4% | — | ||
| Q4 25 | 34.1% | — | ||
| Q3 25 | 32.1% | -35.9% | ||
| Q2 25 | 27.2% | -15.4% | ||
| Q1 25 | 27.4% | -62.2% | ||
| Q4 24 | 34.3% | — | ||
| Q3 24 | 29.8% | -57.2% | ||
| Q2 24 | 29.9% | -83.9% |
| Q1 26 | $0.83 | — | ||
| Q4 25 | $0.77 | $0.32 | ||
| Q3 25 | $0.82 | $-0.16 | ||
| Q2 25 | $0.66 | $-0.06 | ||
| Q1 25 | $0.64 | $-0.21 | ||
| Q4 24 | $0.68 | $-0.14 | ||
| Q3 24 | $0.69 | $-0.15 | ||
| Q2 24 | $0.68 | $-0.33 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $198.4M | $167.9M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.3B | $-302.0M |
| Total Assets | $9.9B | $465.9M |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | $198.4M | — | ||
| Q4 25 | $149.1M | $167.9M | ||
| Q3 25 | $259.0M | $92.4M | ||
| Q2 25 | $218.3M | $86.1M | ||
| Q1 25 | $421.3M | $114.6M | ||
| Q4 24 | $563.1M | $144.8M | ||
| Q3 24 | $452.6M | $144.7M | ||
| Q2 24 | $730.5M | $189.3M |
| Q1 26 | $1.3B | — | ||
| Q4 25 | $1.3B | $-302.0M | ||
| Q3 25 | $1.2B | $-451.4M | ||
| Q2 25 | $1.2B | $-433.5M | ||
| Q1 25 | $1.1B | $-426.2M | ||
| Q4 24 | $1.1B | $-388.7M | ||
| Q3 24 | $1.1B | $-370.2M | ||
| Q2 24 | $1.0B | $-344.2M |
| Q1 26 | $9.9B | — | ||
| Q4 25 | $9.7B | $465.9M | ||
| Q3 25 | $9.8B | $364.0M | ||
| Q2 25 | $9.7B | $347.1M | ||
| Q1 25 | $9.6B | $324.0M | ||
| Q4 24 | $9.5B | $343.8M | ||
| Q3 24 | $9.4B | $314.1M | ||
| Q2 24 | $9.6B | $352.3M |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | — | $45.2M |
| Free Cash FlowOCF − Capex | — | — |
| FCF MarginFCF / Revenue | — | — |
| Capex IntensityCapex / Revenue | — | 0.0% |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $140.3M | $45.2M | ||
| Q3 25 | $38.3M | $-4.3M | ||
| Q2 25 | $16.3M | $-31.4M | ||
| Q1 25 | $27.1M | $-22.6M | ||
| Q4 24 | $175.2M | $-35.0M | ||
| Q3 24 | $19.8M | $-35.3M | ||
| Q2 24 | $40.1M | $-7.2M |
| Q1 26 | — | — | ||
| Q4 25 | $136.3M | — | ||
| Q3 25 | $38.0M | — | ||
| Q2 25 | $15.2M | — | ||
| Q1 25 | $25.0M | — | ||
| Q4 24 | $171.2M | — | ||
| Q3 24 | $19.1M | $-35.5M | ||
| Q2 24 | $39.4M | $-7.3M |
| Q1 26 | — | — | ||
| Q4 25 | 116.5% | — | ||
| Q3 25 | 32.8% | — | ||
| Q2 25 | 13.7% | — | ||
| Q1 25 | 24.3% | — | ||
| Q4 24 | 163.5% | — | ||
| Q3 24 | 18.8% | -68.7% | ||
| Q2 24 | 39.7% | -9.9% |
| Q1 26 | — | — | ||
| Q4 25 | 3.4% | 0.0% | ||
| Q3 25 | 0.3% | 0.0% | ||
| Q2 25 | 1.0% | 0.0% | ||
| Q1 25 | 2.0% | 0.0% | ||
| Q4 24 | 3.8% | 0.0% | ||
| Q3 24 | 0.6% | 0.3% | ||
| Q2 24 | 0.7% | 0.1% |
| Q1 26 | — | — | ||
| Q4 25 | 4.06× | — | ||
| Q3 25 | 1.03× | — | ||
| Q2 25 | 0.54× | — | ||
| Q1 25 | 0.96× | — | ||
| Q4 24 | 5.78× | — | ||
| Q3 24 | 0.65× | — | ||
| Q2 24 | 1.35× | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
BY
Segment breakdown not available.
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
